Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype

Experimental Hematology

Volumn 28, Issue 5, 2000, Pages 558-568

  Decker, Thomas ^a   Schneller, Folker ^a   Kronschnabl, Manuela ^a   Dechow, Tobias ^a   Lipford, Grayson B ^a   Wagner, Hermann ^a   Peschel, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CLL; CpG oligonucleotides; IL 2; Immunotherapy

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; OLIGONUCLEOTIDE;

ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; KINETICS; LEUKEMIA, B-CELL, CHRONIC; MEMBRANE GLYCOPROTEINS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; RECEPTORS, INTERLEUKIN-2; REFERENCE VALUES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034018567     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00144-2     Document Type: Article

References (40)

1. O'Brien S., Del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 85:1995;306.
2. Fluckiger A.C., Rossi J.F., Bussel A., Bryon P., Bancherau J., Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood. 80:1992;3173.
3. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia. a bird of a different feather J Clin Oncol. 17:1999;399.
4. Hivroz C., Grillot-Courvallin C., Brouet J.C., Seligman M. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor IL-2. Eur J Immunol. 16:1986;1001.
5. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv Immunol. 70:1998;1.
6. Fluckiger A.C., Garrone P., Durand I., Galizzi J.P., Bancherau J. Interleukin 10 (IL-10) upregulates functional high affinity receptors on normal and leukemic B lymphocytes. J Exp Med. 178:1993;1473.
7. Karray S., Dautry-Varsat A., Tsudo M., Merle Beral H., Debre P., Galanaud P. IL-4 inhibits the expression of high affinity IL-2 receptors on monoclonal human B cells. J Immunol. 145:1990;1152.
8. Begley C.G., Burton J.D., Tsudo M., Brownstein B.H., Ambrus J.L., Waldmann T.A. Human B lymphocytes express the p75 component of the interleukin 2 receptor. Leuk Res. 14:1990;263.
9. Liang H., Nishioka Y., Reich C.F., Pisetsky D.S., Lipsky P. Activation of human B cells by phosphorothioate oligonucleotides. J Clin Invest. 98:1996;1119.
10. Lipford G.B., Heeg K., Wagner H. Bacterial DNA as immune cell activator. Trends Microbiol. 6:1998;496.
11. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky D.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546.
12. Yi A.K., Krieg A.M. Cutting edge. rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA J Immunol. 161:1998;4493.
13. Häcker H., Mischak H., Miethke T.et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non specific endocytosis and endosomal maturation. Embo J. 17:1998;6230.
14. Yi A.K., Chang M., Peckham D.W., Krieg A.M., Ashman R.F. CpG Oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 160:1998;598.
15. Wang Z., Karras J.G., Colarusso T.P., Foote L.C., Rothstein T.L. Unmethylated CpG motifs protect murine B lymphocytes against FAS-mediated apoptosis. Cell Immunol. 180:1997;162.
16. Bauer M., Wagner H., Heeg K., Lipford G.B. DNA activates human immune cells through a CpG sequence dependent manner. Immunology. 97:1999;699.
17. Decker T., Schneller F., Sparwasser T., Lipford G.B., Wagner H., Peschel C. Immunostimulatory CpG-Oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients. Blood. 95:2000;999.
18. Buhmann R., Nolte A., Westhaus D., Emmerich B., Hallek M. CD40-activated B-Cell chronic lymphocytic leukemia cells for tumor immunotherapy. stimulation of allogeneic versus autologous T cells generate different types of effector cells Blood. 93:1999;1992.
19. Kato K., Cantwell M.J., Sharma S., Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 101:1998;1133.
20. Herr W., Schneider J., Lohse A.W., Meyer zum Büschenfelde K.H., Wölfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma peptide antigens. J Immunol Methods. 191:1996;131.
21. Robb R.J., Greene W.C., Rusk C.M. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med. 160:1984;1126.
22. Roessler E., Grant A., Ju G., Tsudo M., Sugamura K., Walmann T.A. Cooperative interactions between the interleukin-2 receptor alpha and beta chains alter the interleukin-2 binding affinity of the receptor subunits. Proc Natl Acad Sci U S A. 91:1994;3344.
23. Kondo M., Takeshita T., Ishii N.et al. Functional participation of the IL-2 receptor-gamma chain in IL-7 receptor complexes. Science. 263:1994;1453.
24. Foa R., Massaia M., Cardona S.et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells. a possible regulatory role for TNF in the progression of the disease Blood. 76:1990;393.
25. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10 and CD40L. Cell Immunol 161:226.
26. Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on serin residues. J Clin Invest. 100:1997;3140.
27. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell. 82:1995;241.
28. Meinhardt G., Wendtner C.M., Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia. factors and signalling pathways regulating cell growth and survival J Mol Med. 77:1999;282.
29. Lenschow D.J., Walunas T.L., Bluestofne J.A. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 14:1996;233.
30. Fiels P.E., Finch R.J., Gray G.S.et al. B7.1 is a quantitatively stronger costimulus than B7.2 in activation of naive TCR-transgenic T cells. J Immunol. 161:1998;5268.
31. Stremmel C., Greenfield E.A., Howard E., Freeman G.J., Kuchroo V.K. B7-2 expressed on EL4 Lymphoma suppresses antitumor Immunity by an interleukin-4-dependent mechanism. J Exp Med. 189:1999;919.
32. Buschle M., Campana D., Carding S.R., Richard S., Hoffbrand A.V., Brenner M.K. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 177:1993;213.
33. Johnson T.A., Rassenti L.Z., Kipps T.J. Ig VH1 genes expressed in B-cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 158:1997;235.
34. Decker T., Flohr T., Trautmann P.et al. Role of accessory cells in cytokine production by T cells in Chronic B-cell lymphocytic leukemia. Blood. 86:1995;1115.
35. Dazzi F., D'Andrea E., Biasi G.et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol. 75:1995;26.
36. Schultze J.L., Nadler L.M. T cell mediated immunotherapy for B cell lymphoma. J Mol Med. 77:1999;322.
37. Schultze J.L., Seamon M.J., Michalak S., Gribben J.G., Nadler L.M. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma can be expanded in vitro. Blood. 89:1997;3806.
38. Cardoso A., Schultze J.L., Boussiotis V.A.et al. Pre-B acute lymphoblastic leukemia cells may induct T cell anergy to alloantigen. Blood. 88:1996;41.
39. Keilholz U., Conradt C., Legha S.S.et al. Results of Interleukin-2-based treatment in advanced melanoma. a case record-based analysis of 631 patients J Clin Oncol. 16:1998;2921.
40. Cortes J.E., Kantarjian H.M., O'Brien S.et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 85:1999;1506.